Akèy › Maladi selil fòs › Alabama
Etid klinik pou Maladi selil fòs nan Alabama
16 etid pou Maladi selil fòs ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- University Of Alabama, Birmingham
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07187973A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Uni of Alabama at Birmingham, Birmingham
- Univer South Alabama Ped/Onc, Mobile
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06612268A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- University of Alabama Birmingham, Birmingham
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 12 a 55 · Tout sèks · Mizajou Sep 9, 2026 · NCT06546670SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06442761A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- AMR Clinical, Mobile
Ap rekriteFaz 2/3
Laj 12 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05431088The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
Ap rekriteFaz 3
Laj 10 a 65 · Tout sèks · Mizajou Jul 29, 2026 · NCT06975865Early Life Exposures Among Children With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
Ap rekrite
Laj 18 a 50 · Fanm · Mizajou Jul 15, 2026 · NCT05377372Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- University Of Alabama, Birmingham
Ap rekriteFaz 4
6 Months – 100 Years · Tout sèks · Mizajou Jun 8, 2026 · NCT04657822Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Children's of Alabama (MRD-HCT), Birmingham
- Children's of Alabama (NT-DMT), Birmingham
Ap rekriteEtid obsèvasyon
Laj 3 a 20 · Tout sèks · Mizajou Jun 4, 2026 · NCT06941389Cognitive Remediation Intervention to Prepare for Transition of Care
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 2
Laj 10 a 18 · Tout sèks · Mizajou Feb 27, 2026 · NCT05336201A Long-term Follow-up Study in Patients Who Received BEAM-101
- University of Alabama at Birmingham, Birmingham
Ap rekriteEtid obsèvasyon
Laj 14 a 37 · Tout sèks · Mizajou Jan 28, 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- University of South Alabama Medical Center, Mobile
Ap rekrite
Laj 16 a 30 · Tout sèks · Mizajou Jan 7, 2026 · NCT06374238HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
Ap rekriteEtid obsèvasyon
Laj 12 a 80 · Tout sèks · Mizajou Aug 28, 2025 · NCT07145411Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Alabama, Birmingham (UAB), Birmingham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2025 · NCT06385886Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.